Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome

详细信息    查看全文

• 作者：I. Marie ; S. Josse ; O. Decaux ; S. Dominique ; E. Diot ; C. L ; ron ; P. Roblot ; S. Jouneau ; P.Y. Hatron ; K.P. Tiev ; O. Vittecoq ; D. Noel ; L. Mouthon ; J.-F. Menard ; F. Jouen
• 关键词：Antisynthetase syndrome ; Anti-Jo1 antibody ; Anti-PL7 antibody ; Anti-PL12 antibody ; Outcome ; Cancer ; Interstitial lung disease ; Prognostic factors
• 刊名：Autoimmunity Reviews
• 出版年：2012
• 出版时间：August, 2012
• 年：2012
• 卷：11
• 期：10
• 页码：739-745
• 全文大小：208 K

文摘

The aims of the present study were to: compare the characteristics between antisynthetase syndrome (ASS) patients with anti-Jo1 antibody and those with anti-PL7/PL12 antibody. The medical records of 95 consecutive patients with ASS were reviewed. Seventy-five of these patients had anti-Jo1 antibody; the other patients had anti-PL7 (n = 15) or anti-PL12 (n = 5) antibody. At ASS diagnosis, the prevalence of myalgia (p = 0.007) and muscle weakness (p = 0.02) was significantly lower in the group of anti-PL7/PL12-positive patients than in those with anti-Jo1 antibody; median value of CK (p = 0.00003) was also lower in anti-PL7/PL12 patients. Anti-Jo1 positive patients developed more rarely myositis resolution (21.3 % vs. 46.2 % ); in addition, the overall recurrence rate of myositis was higher in anti-Jo1 positive patients than in patients with anti-PL7/PL12 antibody (65.9 % vs. 19.4 % ). Anti-Jo1-positive patients, compared with those with anti-PL7/PL12 antibody, more often experienced: joint involvement (63.3 % vs. 40 % ) and cancer (13.3 % vs. 5 % ). By contrast, anti-PL7/PL12 positive patients, compared with those with anti-Jo1 antibody, more commonly exhibited: ILD (90 % vs. 68 % ); in anti-PL7/PL12 positive patients, ILD was more often symptomatic at diagnosis, and led more rarely to resolution of lung manifestations (5.6 % vs. 29.4 % ). Finally, the group of anti-PL7/PL12 positive patients more commonly experienced gastrointestinal manifestations related to ASS (p = 0.02). Taken together, although anti-Jo1 positive patients with ASS share some features with those with anti-PL7/PL12 antibody, they exhibit many differences regarding clinical phenotype and long-term outcome. Our study underscores that the presence of anti-Jo1 antibody results in more severe myositis, joint impairment and increased risk of cancer. On the other hand, the presence of anti-PL7/PL12 antibody is markedly associated with: early and severe ILD, and gastrointestinal complications. Thus, our study interestingly indicates that the finding for anti-Jo1 and anti-PL7/PL12 antibodies impacts both the long-term outcome and prognosis of patients with ASS.